Trulicity Geriatric (65+) Caregiver Administration Guidance

Does Trulicity dosing change after age 65?

The label's adult dosage section sets one schedule for all adults and does not carve out a separate starting dose, ceiling or titration interval for people over 65 [1]. Dulaglutide pharmacokinetics were not affected in a clinically relevant way by age, sex, race, body weight, or renal or hepatic impairment [1].

The labeled adult schedule is 0.75 mg subcutaneously once weekly, rising to 1.5 mg after at least 4 weeks if more glycemic control is needed, then to 3 mg and 4.5 mg in 1.5 mg steps, each step after at least 4 weeks on the current dose. The adult maximum is 4.5 mg once weekly [1].

Higher doses buy modest extra glucose lowering. At 36 weeks in AWARD-11, the 4.5 mg group had a larger HbA1c reduction than the 1.5 mg group: 1.77 versus 1.54 percentage points using the treatment-regimen analysis [2].

What the label says to check before the first dose

Three items come straight from the label.

Contraindications. Trulicity is contraindicated in a patient with a personal or family history of medullary thyroid carcinoma, with multiple endocrine neoplasia syndrome type 2 (MEN 2), or with a prior serious hypersensitivity reaction to dulaglutide or any product component [1].

The boxed warning. In rats, dulaglutide caused dose-related thyroid C-cell tumors, and it is unknown whether it does so in humans [1]. The label asks clinicians to counsel patients about the potential risk and about symptoms of thyroid tumors such as a mass in the neck, difficulty swallowing, difficulty breathing, or persistent hoarseness [1]. Routine serum calcitonin testing or thyroid ultrasound is of uncertain value for early detection [1].

Training. The label states that patients and caregivers should be trained on proper injection technique prior to starting, and it points to the Instructions for Use [1].

Two more label items matter in an older household. Trulicity is not recommended in patients with severe gastroparesis [1]. And the label warns about pulmonary aspiration during general anesthesia or deep sedation, asking that healthcare providers be told about any planned surgery or procedure [1].

The weekly injection: timing, sites and missed doses

Trulicity goes in once weekly at any time of day, with or without food, into the abdomen, thigh or upper arm, rotating the site with each dose [1]. When it is used alongside insulin, the label directs that the two be given as separate injections and never mixed; the same body region is acceptable, but the two sites should not be next to each other [1].

If a dose is missed, the label says to give it as soon as possible when at least 3 days (72 hours) remain before the next scheduled dose, and otherwise to skip it and give the next dose on the usual day [1]. The weekly day can be moved as long as the last dose was given 3 or more days before the new day [1].

Hypoglycemia: the risk that changes with other diabetes drugs

In the label's placebo-controlled trial adding Trulicity to metformin, a glucose level below 54 mg/dL occurred in 0.3% of patients on 0.75 mg and 0.7% on 1.5 mg versus 0% on placebo [1]. The picture changes with insulin or a sulfonylurea:

• With insulin glargine, with or without metformin: 14.7% on Trulicity 1.5 mg versus 9.3% on placebo for glucose below 54 mg/dL [1].
• With glimepiride: 3.3% on Trulicity 1.5 mg versus 0% on placebo [1].
• In a 78-week trial with a sulfonylurea: glucose below 54 mg/dL in 20% of patients on 0.75 mg and 21% on 1.5 mg, with severe hypoglycemia in 0% and 0.7% [1].

The label's instruction to prescribers is to consider reducing the dose of the insulin secretagogue or insulin when Trulicity is started, to lower the hypoglycemia risk, and to educate patients on the signs and symptoms of hypoglycemia [1]. For a caregiver, it helps to know whether a sulfonylurea or insulin is on the medication list, since hypoglycemia was more frequent with those combinations in the label's trials [1].

Nausea, vomiting and the dehydration-kidney link

Gastrointestinal effects are the most common adverse reactions, and the label gives exact rates from the adult placebo-controlled pool: nausea 12.4% at 0.75 mg and 21.1% at 1.5 mg versus 5.3% on placebo; diarrhea 8.9% and 12.6% versus 6.7%; vomiting 6.0% and 12.7% versus 2.3% [1]. Any gastrointestinal reaction was reported by 32% and 41% versus 21%, and 1.3% and 3.5% stopped treatment for gastrointestinal reasons versus 0.2% on placebo [1]. Severe gastrointestinal reactions were reported in 2.2% (0.75 mg) and 4.3% (1.5 mg) versus 1.4% on placebo, and most events were mild to moderate [1].

In REWIND, 47.4% of dulaglutide patients versus 34.1% of placebo patients reported a gastrointestinal adverse event over a median 5.4 years [3].

The safety consequence the label highlights is acute kidney injury from volume depletion. Postmarketing reports of kidney injury, some requiring hemodialysis, occurred mostly in patients whose gastrointestinal reactions caused dehydration, and the label asks that renal function be monitored in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1].

A 2026 qualitative review of 37 completed Phase 4 trials of GLP-1 receptor agonists as a class in adults 65 and older (seven of the trials involved dulaglutide) reported gastrointestinal intolerance at rates of 15% to 30% and hypoglycemia under 5% [4].

Heart protection, and who was actually studied

REWIND enrolled 9,901 adults aged 50 and older with type 2 diabetes and either previous cardiovascular disease or cardiovascular risk factors; 31.5% had established cardiovascular disease. They received dulaglutide 1.5 mg weekly or placebo for a median of 5.4 years. The primary composite of non-fatal heart attack, non-fatal stroke or cardiovascular death occurred in 12.0% versus 13.4% (hazard ratio 0.88, 95% CI 0.79 to 0.99; p=0.026) [3]. All-cause death was 10.8% versus 12.0%, which was not a significant difference [3]. The Trulicity label reports fatal or non-fatal stroke in 3.2% of the dulaglutide group versus 4.1% of the placebo group [1].

The cardiovascular indication covers adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors, so a 65-year-old with diabetes and several risk factors can qualify without a prior heart attack or stroke [1].

The trials say little about this age group specifically. In the adult placebo-controlled pool behind the label's adverse reaction tables, the mean age was 56 and 1% of patients were 75 or older [1].

Signs that need urgent medical attention

The label's own action statements are the clearest guide to what cannot wait.

• Pancreatitis. Watch for persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. If pancreatitis is suspected, the label directs that Trulicity be discontinued and appropriate management started [1]. For class context, a 2017 meta-analysis of 113 randomized trials of GLP-1 receptor agonists found pancreatitis incidence no different from comparator arms (MH-OR 0.93, 95% CI 0.65 to 1.34) [5].
• Serious allergic reactions. Anaphylaxis and angioedema have been reported. The label directs that Trulicity be discontinued, standard care given, and the patient monitored until signs and symptoms resolve [1].
• Gallbladder disease. If gallstones or gallbladder inflammation are suspected, gallbladder studies are indicated [1].
• Eye changes. Diabetic retinopathy complications were reported in a cardiovascular outcomes trial, and patients with a history of diabetic retinopathy should be monitored [1].
• Dehydration. Persistent vomiting or diarrhea is the setting in which the label asks for renal function monitoring [1].